MNG121
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.369
- TGF_BETA_SIGNALING+0.367
- ANGIOGENESIS+0.355
- HEDGEHOG_SIGNALING+0.246
- ESTROGEN_RESPONSE_LATE+0.214
- UV_RESPONSE_DN+0.205
- CHOLESTEROL_HOMEOSTASIS+0.188
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.176
- HYPOXIA+0.173
- ANDROGEN_RESPONSE+0.150
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.523
- MYC_TARGETS_V2-0.518
- MYC_TARGETS_V1-0.477
- DNA_REPAIR-0.368
- WNT_BETA_CATENIN_SIGNALING-0.216
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.194
- E2F_TARGETS-0.175
- G2M_CHECKPOINT-0.158
- INTERFERON_GAMMA_RESPONSE-0.122
- FATTY_ACID_METABOLISM-0.121
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG11 | — | — | 0.841 |
| 2 | MNG306 | — | — | 0.827 |
| 3 | MNG359 | — | — | 0.817 |
| 4 | MNG629 | — | — | 0.816 |
| 5 | TCGA-50-6673-01A-11R-1949-07 | — | cohortA1 | 0.806 |
| 6 | TCGA-55-6981-01A-11R-1949-07 | — | cohortA1 | 0.796 |
| 7 | TCGA-FD-A3SL-01A-21R-A22U-07 | — | — | 0.796 |
| 8 | MNG119 | — | — | 0.793 |
| 9 | MNG115 | — | — | 0.787 |
| 10 | MNG931 | — | — | 0.781 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.369 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.367 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.355 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.246 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.214 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.205 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.188 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.176 | Inavolisib | — uncovered |
| HYPOXIA | 0.173 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| MYOGENESIS | 0.144 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.144 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.143 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.139 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.121 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.110 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.098 | Cobimetinib | — uncovered |